Post-ASH 2022 iwMPNs

17 January 2023 | Virtual Meeting

Expert-led presentations & discussions on key abstracts in MPNs from ASH 2022

The Post-ASH 2022 iwMPNs Virtual Workshop took place on 17 January 2023, and featured a series of short presentations on selected abstracts in myeloproliferative neoplasms from the 64th ASH Annual Meeting presented by experts with interactive panel discussions after each session.

Combination and Emerging Targeted Therapies in Myelofibrosis Plenary review PV, ET low risk MF same drugs new data new endpoints? Atypical MPN Mastocytosis

Session 1: Combination and Emerging Targeted Therapies in Myelofibrosis

Ruxolitinib and pegylated IFN alfa-2a in patients with myelofibrosis

Jean-Jacques Kiladjian Saint-Louis Hospital & Paris Diderot University, Paris, France

Efficacy and safety of add-on parsaclisib to ruxolitinib therapy in myelofibrosis

Abdulraheem Yacoub University of Kansas Medical Center, Kansas City, KS, United States

Navitoclax and ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis

Francesco Passamonti University of Insubria, Varese, Italy

Pelabresib with ruxolitinib for JAK inhibitor treatment-naïve patients

John Mascarenhas Icahn School of Medicine at Mount Sinai, New York City, NY, United States

Panel discussion

TP-3654 in pts previously treated with/ineligible for JAK inhibitor therapy

Raajit Rampal Memorial Sloan Kettering Cancer Center

Primary Analysis of the FREEDOM Trial

Vikas Gupta Princess Margaret Cancer Centre, Toronto, Canada

Updated Results from the Momentum Phase III Study

Aaron Gerds Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, United States

Pacritinib is a potent ACVR1 Inhibitor in patients with MF

Stephen Oh Washington University in St. Louis, St. Louis, MO, United States

Panel discussion

Session 2: Plenary review

Review of plenary presentation 6, discovery of INCA033989

Bethan Psaila University of Oxford, Oxford, United Kingdom

Panel discussion

794257347

Session 3: PV, ET low risk MF same drugs new data new endpoints? Atypical MPN Mastocytosis

Ruxolitinib vs best available therapy for PV

Claire Harrison Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom

Bomedemstat (IMG-7289) for treating ET

Harinder Gill University of Hong Kong, Hong Kong

Bone marrow fibrosis changes do not correlate with efficacy outcomes in MF

Stephen Oh Washington University in St. Louis, St. Louis, MO, United States

Panel discussion

Avapritinib in patients with advanced systemic mastocytosis

Deepti Radia Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

Results from the FIGHT-203 study of pemigatinib

Srdan Verstovsek The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Panel discussion

The continued success of the post-ASH meetings is in no small part due to the ongoing funding of supporters, allowing unique opportunities for clinicians to be brought together to facilitate interactive and stimulating debates to help improve patient outcomes.
For more information about supporting future meetings and activities, please contact us here.

For the latest updates in myeloproliferative neoplasms, visit The MPN Channel

Post-ASH 2022 iwMPNs

Post-ASH 2022 iwMPNs

Sign-up for our Newsletter!